152 related articles for article (PubMed ID: 37395206)
1. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes.
Ogawa Y; Nakahara T; Ando Y; Yamaoka K; Fujii Y; Uchikawa S; Fujino H; Ono A; Murakami E; Kawaoka T; Miki D; Yamauchi M; Tsuge M; Imamura M; Oka S
Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):989-996. PubMed ID: 37395206
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
[TBL] [Abstract][Full Text] [Related]
3. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
[TBL] [Abstract][Full Text] [Related]
4. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Euh W; Lim S; Kim JW
Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
[TBL] [Abstract][Full Text] [Related]
5. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors.
Lombardi R; Mantovani A; Cespiati A; Francione P; Maffi G; Del Zanna E; Maffeis C; Colecchia A; Passigato N; Ferrarese A; Cusumanu CD; Villani R; Orsi E; Grancini V; Airaghi L; Bignamini D; Serviddio G; Targher G; Dongiovanni P; Fargion S; Fracanzani AL
Dig Liver Dis; 2024 Apr; 56(4):551-558. PubMed ID: 37845152
[TBL] [Abstract][Full Text] [Related]
6. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
Shinozaki S; Tahara T; Lefor AK; Ogura M
J Med Invest; 2020; 67(3.4):280-284. PubMed ID: 33148902
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
[TBL] [Abstract][Full Text] [Related]
8. The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease.
Yamashima M; Miyaaki H; Miuma S; Shibata H; Sasaki R; Haraguchi M; Fukushima M; Nakao K
Intern Med; 2019; 58(14):1987-1992. PubMed ID: 31308341
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
10. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of Transient Elastography for Non-Invasive Diagnosis of Liver Fibrosis in Pediatric Non-Alcoholic Steatohepatitis.
Kwon YD; Ko KO; Lim JW; Cheon EJ; Song YH; Yoon JM
J Korean Med Sci; 2019 Jun; 34(23):e165. PubMed ID: 31197983
[TBL] [Abstract][Full Text] [Related]
12. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
15. Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists.
Gracen L; Muthukumara W; Aikebuse M; Russell A; O'Beirne J; Irvine KM; Williams S; Puri G; Valery PC; Hayward KL; Powell EE
Ann Hepatol; 2023; 28(6):101142. PubMed ID: 37468097
[TBL] [Abstract][Full Text] [Related]
16. The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan-aspartate aminotransferase to predict severity of liver disease in children.
Chaidez A; Pan Z; Sundaram SS; Boster J; Lovell M; Sokol RJ; Mack CL
Hepatol Commun; 2022 Nov; 6(11):3015-3023. PubMed ID: 36069338
[TBL] [Abstract][Full Text] [Related]
17. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
18. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials.
Jin Z; Yuan Y; Zheng C; Liu S; Weng H
J Diabetes Complications; 2023 Aug; 37(8):108558. PubMed ID: 37499274
[TBL] [Abstract][Full Text] [Related]
19. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
20. When the liver gets stiff, the tough get moving.
Nguyen TH; Wardell R; Chitturi S; Teoh N; Farrell G
J Gastroenterol Hepatol; 2020 Jun; 35(6):953-959. PubMed ID: 31867782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
